
Please try another search
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Oh-Woong Kwon | - | - | Member of the Scientific Advisory Board |
Jin Kuk Kim | - | - | Member of the Scientific Advisory Board |
Dong Hyun Lee | - | - | Member of the Scientific Advisory Board |
Gong Je Seong | - | - | Member of the Scientific Advisory Board |
Sung-Jin Lee | 84 | - | Member of the Scientific Advisory Board |
Na-Gyong Lee | - | - | Member of the Scientific Advisory Board |
Choun-ki Joo | - | - | Member of the Scientific Advisory Board |
Doo-Sik Kim | 74 | - | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review